CompletedNCT06734585

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Studying Acute promyelocytic leukemia

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Astellas Pharma Singapore Pte. Ltd.
Principal Investigator: Central Contact
Astellas Pharma Singapore Pte. Ltd.
Intervention: Gilteritinib(drug)
Enrollment: 114 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2025 – 2025

Study locations (18)

AU61001, Melbourne, Australia
AU61002, Melbourne, Australia
BR55004, Fortaleza, Brazil
BR55002, Porto Alegre, Brazil
BR55001, São Paulo, Brazil
BR55003, São Paulo, Brazil
CN86003, Shanghai, China
CN86004, Suzhou, China
CN86001, Tianjin, China
HK852001, Hong Kong, Hong Kong
KR82004, Busan, South Korea
KR82005, Gwangju, South Korea
KR82001, Seoul, South Korea
KR82002, Seoul, South Korea
KR82003, Seoul, South Korea
+3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06734585 on ClinicalTrials.gov

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute promyelocytic leukemia →

← Back to all trials